PharmaTimes https://pharmatimes.com in-depth news, features and insights for the pharmaceutical and healthcare sectors Mon, 12 Oct 2026 10:01:32 +0000 en-US hourly 1 https://pharmatimes.com/wp-content/uploads/2023/11/PT-icon-150x150.png PharmaTimes https://pharmatimes.com 32 32 232894315 RougeTx launches with $58 million series A financing for HHT therapy https://pharmatimes.com/news/rougetx-launches-with-58-million-series-a-financing-for-hht-therapy/ Thu, 15 Oct 2026 09:54:10 +0000 https://pharmatimes.com/?p=105198 New company to advance first‑in‑class treatment

]]> 105198 Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease https://pharmatimes.com/news/lundbeck-presents-phase-1b-data-for-lu-af28996-in-advanced-parkinsons-disease/ Thu, 15 Oct 2026 09:53:12 +0000 https://pharmatimes.com/?p=105201 Phase 2 development underway as DARE2 trial begins

]]> 105201 Bespak and SNBL agree global access deal for FDA‑approved nasal device https://pharmatimes.com/news/bespak-and-snbl-agree-global-access-deal-for-fda-approved-nasal-device/ Wed, 14 Oct 2026 09:42:34 +0000 https://pharmatimes.com/?p=105196 Partnership expands Bespak’s intranasal dry powder capabilities

]]> 105196 NEMLUVIO data show sustained three‑year responses in atopic dermatitis https://pharmatimes.com/news/nemluvio-data-show-sustained-three-year-responses-in-atopic-dermatitis/ Wed, 14 Oct 2026 09:36:45 +0000 https://pharmatimes.com/?p=105192 New long‑term results reinforce efficacy across AD and PN

]]> 105192 SMC accepts AQUIPTA for eligible migraine patients in Scotland https://pharmatimes.com/news/smc-accepts-aquipta-for-eligible-migraine-patients-in-scotland/ Tue, 13 Oct 2026 09:39:42 +0000 https://pharmatimes.com/?p=105194 New option offers acute treatment for adults with migraine

]]> 105194 MINT study results strengthen real‑world evidence for mogamulizumab https://pharmatimes.com/news/mint-study-results-strengthen-real-world-evidence-for-mogamulizumab/ Tue, 13 Oct 2026 09:31:32 +0000 https://pharmatimes.com/?p=105190 Final analysis shows durable outcomes in MF and SS

]]> 105190 SMC accepts vutrisiran for eligible patients in Scotland https://pharmatimes.com/news/smc-accepts-vutrisiran-for-eligible-patients-in-scotland/ Mon, 12 Oct 2026 09:36:38 +0000 https://pharmatimes.com/?p=105189 First long‑acting therapy targeting root cause of ATTR‑CM

]]> 105189 NHS Blood and Transplant partners with Northwest Biotherapeutics https://pharmatimes.com/news/nhs-blood-and-transplant-partners-with-northwest-biotherapeutics/ Mon, 12 Oct 2026 09:33:09 +0000 https://pharmatimes.com/?p=105188 Collaboration to expand personalised cancer immunotherapy

]]> 105188 Laverock unveils new in vivo programmes in oncology https://pharmatimes.com/news/laverock-unveils-new-in-vivo-programmes-in-oncology/ Thu, 08 Oct 2026 11:23:56 +0000 https://pharmatimes.com/?p=105170 Company expands pipeline into car‑t and genetic medicine

]]> 105170 Atrogi reports human data showing muscle gains with ATR‑258 https://pharmatimes.com/news/atrogi-reports-human-data-showing-muscle-gains-with-atr-258/ Thu, 08 Oct 2026 10:09:27 +0000 https://pharmatimes.com/?p=105181 Early findings support phase 2 plans for 2027

]]> 105181